Crawford C R, Cass C E, Young J D, Belt J A
Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Biochem Cell Biol. 1998;76(5):843-51. doi: 10.1139/bcb-76-5-843.
Previous studies of nucleoside transport in mammalian cells have identified two types of activities: the equilibrative nucleoside transporters and concentrative, Na+-nucleoside cotransporters. Characterization of the concentrative nucleoside transporters has been hampered by the presence in most cells and tissues of multiple transporters with overlapping permeant specificities. With the recent cloning of cDNAs encoding rat and human members of the concentrative nucleoside transporter (CNT) family, it is now possible to study the concentrative transporters in isolation by use of functional expression systems. We report here the isolation of a nucleoside transport-deficient subline of L1210 mouse leukemia (L1210/DNC3) that is a suitable recipient for stable expression of cloned nucleoside transporter cDNAs. We have used L1210/DNC3 as the recipient in gene transfer studies to develop a stable cell line (L1210/DU5) that produces the recombinant concentrative nucleoside transporter with selectivity for pyrimidine nucleosides (CNT1) that was initially identified in rat intestine (Q.Q. Huang, S.Y. Yao, M.W. Ritzel, A.R.P. Paterson, C.E. Cass, and J.D. Young. 1994. J. Biol. Chem. 269: 17,757-17,760). L1210/DU5 was used to examine the permeant selectivity of recombinant rat CNT1 by comparing a series of nucleoside analogs with respect to (i) inhibition of inward fluxes of [3H]thymidine, (ii) initial rates of transport of 3H-analog, and (iii) cytotoxicity to L1210/DU5 versus the parental transport-deficient cell line. By all three criteria, recombinant CNT1 transported 5-fluoro-2'-deoxyuridine and 5-fluorouridine well and cytosine arabinoside poorly. Although some purine nucleosides (2'-deoxyadenosinedeoxyadeno-2'-deoxyadenosine, 7-deazaadenosine) were potent inhibitors of CNT1, they were poor permeants when uptake was measured directly by analysis of isotopic fluxes or indirectly by comparison of cytotoxicity ratios. We conclude that comparison of analog cytotoxicity to L1210/DU5 versus L1210/DNC3 is a reliable indirect predictor of transportability, suggesting that cytotoxicity assays with a panel of such cell lines, each with a different recombinant nucleoside transporter, would be a valuable tool in the development of antiviral and antitumor nucleoside analogs.
平衡核苷转运体和浓缩型、Na⁺-核苷共转运体。由于大多数细胞和组织中存在多种具有重叠通透特异性的转运体,浓缩型核苷转运体的特性研究受到了阻碍。随着最近编码浓缩型核苷转运体(CNT)家族大鼠和人类成员的cDNA的克隆,现在可以通过使用功能表达系统来单独研究浓缩型转运体。我们在此报告分离出L1210小鼠白血病的核苷转运缺陷亚系(L1210/DNC3),它是克隆核苷转运体cDNA稳定表达的合适受体。我们在基因转移研究中使用L1210/DNC3作为受体,以开发出一种稳定细胞系(L1210/DU5),该细胞系产生对嘧啶核苷具有选择性的重组浓缩型核苷转运体(CNT1),最初是在大鼠肠道中鉴定出来的(Q.Q. Huang,S.Y. Yao,M.W. Ritzel,A.R.P. Paterson,C.E. Cass,和J.D. Young。1994。J. Biol. Chem. 269:17,757 - 17,760)。L1210/DU5用于通过比较一系列核苷类似物在以下方面来检查重组大鼠CNT1的通透选择性:(i)对[³H]胸苷内向通量的抑制,(ii)³H-类似物的初始转运速率,以及(iii)对L1210/DU5与亲本转运缺陷细胞系的细胞毒性。根据所有这三个标准,重组CNT1对5-氟-2'-脱氧尿苷和5-氟尿苷转运良好,对阿糖胞苷转运较差。尽管一些嘌呤核苷(2'-脱氧腺苷、7-脱氮腺苷)是CNT1的强效抑制剂,但当通过同位素通量分析直接测量摄取或通过比较细胞毒性比率间接测量时,它们是较差的通透物。我们得出结论,比较L12